ArticleFrontiers in oncology2026
Neoadjuvant camrelizumab in combination with chemotherapy followed by sequential radical surgery for locally advanced esophageal squamous cell carcinoma: postoperative pathological remission characteristics and influencing factors.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant camrelizumab combined with chemotherapy has shown favorable efficacy and safety profiles in the treatment of locally advanced esophageal squamous cell carcinoma (LA-ESCC). This study focused on the clinical data of patients treated with camrelizumab plus chemotherapy before and after neoadjuvant treatment, with the aims of exploring predictive markers for pathological response after radical resection, systematically verifying the safety of this regimen, and investigating indicators associated with long-term prognosis of patients. Methods: A retrospective analysis was conducted on patients with histologically confirmed LA-ESCC who were treated at the First Affiliated Hospital of Zhengzhou University between November 2019 and September 2024. Peripheral blood inflammatory and nutritional parameters, adverse events, and perioperative surgical outcomes were collected and recorded before and after neoadjuvant therapy. Disease-free survival (DFS) and overall survival (OS) were used as long-term endpoints to evaluate the impact of pathological response on patient prognosis. Results: A total of 115 patients with LA-ESCC who underwent radical surgery after neoadjuvant camrelizumab combined with chemotherapy were finally included. Among them, 106 patients (92.2%) experienced treatment-related adverse events, of which only 16 cases were grade 3 or higher. Major pathological response (MPR) was achieved in 82 patients, with an MPR rate of 71.3%. The median follow-up duration was 43 months. Neither median overall survival (mOS) nor median disease-free survival (mDFS) was reached in the MPR group, while mOS and mDFS in the non-major pathological response (NMPR) group were 48 months and 41 months, respectively, indicating a significantly better prognosis in the MPR group than the NMPR group. The neutrophil-to-lymphocyte ratio (NLR) after neoadjuvant therapy was significantly different between patients with different pathological responses (P < 0.05). Conclusion: For patients with LA-ESCC, neoadjuvant camrelizumab combined with chemotherapy followed by radical surgery can significantly improve the rate of complete pathological response (CPR) and MPR, with a favorable overall safety profile. This study further confirms that lower NLR after neoadjuvant therapy is associated with better postoperative pathological remission, suggesting that NLR may serve as a convenient and readily available biomarker for predicting the efficacy of neoadjuvant immunochemotherapy in LA-ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.